Bruker at ESAC 2026

ESAC brings together leading scientists and decision-makers from life science, biopharma, and applied analytical fields to discuss emerging challenges, new technologies, and future directions in analytical chemistry.

Throughout the program, Bruker customers and collaborators will share real-world results and application insights, highlighting how advanced analytical approaches—particularly mass spectrometry—enable deeper understanding across a wide range of research areas.

Meet the Bruker team on site to discuss how these approaches translate into practical workflows for your own research and analytical challenges:

• Discuss analytical challenges inspired by ESAC presentations
• Explore mass spectrometry–based workflows across life science, pharma, and applied research
• Exchange ideas with Bruker experts and fellow scientists

Program

The ESAC 2026 agenda features several presentations from researchers and industry experts who rely on mass spectrometry to generate actionable insights. Selected highlights include:

Keynote presentation

From Invisible Impurities to Actionable Insight: Host Cell Protein Identification by LC–MS in Biopharmaceuticals

• 9:45 - 10:15 am CEST
• Max Kraner, Ph.D., MBA, Head of Department MS Characterization, Novo Nordisk, Copenhagen, Denmark

Host cell proteins (HCPs) remain one of the most complex and underestimated impurity classes in biopharmaceutical development. While often present at trace levels, their potential impact on product stability, efficacy, and immunogenicity makes their reliable detection and identification a critical challenge. This becomes particularly important as drug modalities, expression systems, and manufacturing processes evolve.

In this keynote, Max Kraner will discuss how advanced LC–MS–based strategies identify HCPs across drug product development. Drawing on real-world experience from large-molecule drug development, the talk will explore the transition from traditional global HCP assays, like ELISA, toward hybrid and MS-driven approaches, including peptide-level quantification and activity-based enrichment and subsequent identification. The presentation will highlight practical considerations for implementing MS-based HCP workflows in biopharmaceutical environments, discuss current limitations and emerging opportunities. He will outline how mass spectrometry can move from a troubleshooting tool to a strategic guide for process development in biopharmaceutical R&D.

Applied Sciences Track 

Investigating Lignin Structure and Enzymatic Degradation Products

• 10:20 - 10:50 am CEST
• Jane Wittrup Agger, Associate Professor, DTU Bioengineering, Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark

Life Science Track 

Resolving Pollutant Degradation in Biofilms Spatially on the Micrometre Range

• 12:00 - 12:30 pm CEST
• Kai Bester, Ph.D., Professor, Department of Environmental Science, Aarhus University, Roskilde, Denmark
• Prasad Phapale, Ph.D., Associate Professor, Department of Environmental Science, Aarhus University, Roskilde, Denmark

Pharmaceutical Track 

MHC-Associated Peptide Proteomics for Predicting Biotherapeutic Immunogenicity

• 2:30 - 3:00 pm CEST
• Sarah Jørgensen, Ph.D., Research Scientist, Novo Nordisk, Copenhagen, Denmark

If you’d like to attend ESAC 2026, registration and detailed conference information are available via the official ESAC website and managed directly by the conference organizers.